Strides Pharma Declines 1.95%: Mixed Technicals and Attractive Valuation Shape Week

Monday, 23 February: Technical Momentum Shifts Amid Mixed Signals

Strides Pharma began the week on a cautiously optimistic note, gaining 0.70% to close at Rs.874.05, outperforming the Sensex’s 0.39% rise. However, technical analysis revealed a shift from a mildly bullish stance to a sideways trend, signalling consolidation. The stock traded within a narrow intraday range of Rs.862.55 to Rs.874.00, reflecting subdued volatility.

Key momentum indicators such as the MACD and KST oscillators turned mildly bearish on weekly and monthly timeframes, while the RSI presented a mixed picture—neutral on weekly charts but bearish monthly. Bollinger Bands suggested mild bearishness short-term but mild bullishness longer-term. Daily moving averages remained mildly bullish, indicating some short-term support.

On-balance volume (OBV) was mildly bearish weekly but neutral monthly, suggesting balanced volume trends without strong conviction. The stock’s 52-week range of Rs.551.00 to Rs.1,024.90 underscored the potential for volatility ahead. MarketsMOJO downgraded the Mojo Grade to Sell with a score of 48.0 on 16 February, reflecting caution amid these mixed signals.

Tuesday, 24 February: Price Correction Amid Broader Market Weakness

On 24 February, Strides Pharma corrected sharply, falling 1.50% to Rs.860.90, underperforming the Sensex’s 0.78% decline. The increased volume of 3,076 shares indicated heightened selling pressure. This decline aligned with the technical momentum shift observed the previous day, as the stock struggled to maintain its earlier gains amid sector and market headwinds.

Wednesday, 25 February: Valuation Upgraded to Very Attractive Amid Sector Volatility

Midweek, Strides Pharma edged up 0.17% to Rs.862.40, marginally outperforming the Sensex’s 0.41% gain. This movement coincided with a significant valuation reassessment. The company’s price-to-earnings (P/E) ratio stood at 14.43, considerably lower than peers such as Ajanta Pharma (36.33) and Emcure Pharma (29.85), signalling relative undervaluation.

The price-to-book value (P/BV) ratio of 2.89 and EV/EBITDA of 10.59 further reinforced the stock’s appeal. Compared to sector heavyweights like J B Chemicals & Pharmaceuticals (EV/EBITDA 28.96) and AstraZeneca Pharma (75.23), Strides Pharma’s valuation metrics were notably conservative.

Return on capital employed (ROCE) and return on equity (ROE) were solid at 15.60% and 15.82%, respectively, supporting the valuation upgrade. Despite a modest dividend yield of 0.46%, the company’s focus on reinvestment and growth was evident. The valuation grade was upgraded from attractive to very attractive, reflecting improved price appeal amid sector volatility.

However, the Mojo Grade remained at Sell with a score of 48.0, indicating caution due to near-term uncertainties despite the valuation improvement.

Thursday, 26 February: Price Stabilises Amid Mixed Market Signals

Strides Pharma’s price remained virtually unchanged at Rs.862.25 (-0.02%), while the Sensex gained 0.19%. The stock’s volume declined to 2,988 shares, suggesting a pause in directional momentum. This stability followed the valuation upgrade and technical consolidation, reflecting investor indecision amid mixed signals.

Friday, 27 February: Week Ends with Decline Amid Market Weakness

The week concluded with Strides Pharma falling 1.30% to Rs.851.05, underperforming the Sensex’s 1.16% drop. Volume was moderate at 2,394 shares. The decline capped a week of mixed technical signals and valuation shifts, with the stock ending below its opening price of Rs.874.05 on Monday.

This price weakness reflected broader market volatility and sector-specific challenges, despite the company’s improved valuation metrics. The stock’s 52-week range remained wide, underscoring ongoing uncertainty in near-term price direction.

Key Takeaways

Positive Signals: The upgrade in valuation to very attractive highlights Strides Pharma’s relative undervaluation compared to sector peers, supported by solid ROCE and ROE metrics. The stock’s long-term returns remain robust, with a three-year gain exceeding 500%, significantly outpacing the Sensex.

Cautionary Signals: Technical momentum shifted to a sideways trend with mildly bearish MACD and KST indicators, and a bearish monthly RSI. The Mojo Grade downgrade to Sell and recent price declines suggest near-term uncertainty. Volume trends do not strongly support price levels, indicating a lack of conviction among investors.

Market Context: The pharmaceuticals sector faces regulatory and pricing pressures, contributing to volatility. Strides Pharma’s conservative valuation may appeal to value investors, but sector headwinds and mixed technical signals warrant a cautious stance.

Conclusion

Strides Pharma Science Ltd’s week was characterised by a complex interplay of technical consolidation and valuation recalibration. While the stock underperformed the Sensex with a 1.95% decline, its upgraded valuation metrics present a compelling value proposition within a volatile sector. The mixed technical signals and downgrade in Mojo Grade advise prudence, suggesting investors should monitor evolving momentum and sector developments closely. Overall, the stock remains in a consolidation phase, balancing attractive valuation against near-term uncertainties.

Limited Period Only. Start at Rs. 9,999 - Get MojoOne for 1 Year + 3 Months FREE (60% Off) Get 71% Off →